Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients

Abstract

BackgroundDuring posttreatment surveillance of head and neck cancer patients, imaging is insufficiently accurate for the early detection of relapsing disease. Free circulating tumor DNA (ctDNA) may serve as a novel biomarker for monitoring tumor burden during posttreatment surveillance of these patients. In this exploratory study, we investigated whether low level ctDNA in plasma of head and neck cancer patients can be detected using Droplet Digital PCR (ddPCR).Methods TP53 mutations were determined in surgically resected primary tumor samples from six patients with high stage (II-IV), moderate to poorly differentiated head and neck squamous cell carcinoma (HNSCC). Subsequently, mutation specific ddPCR assays were designed. Pretreatment plasma samples from these patients were examined on the presence of ctDNA by ddPCR using the mutation-specific assays. The ddPCR results were evaluated alongside clinicopathological data.ResultsIn all cases, plasma samples were found positive for targeted TP53 mutations in varying degrees (absolute quantification of 2.2–422 mutational copies/ml plasma). Mutations were detected in wild-type TP53 background templates of 7667–156,667 copies/ml plasma, yielding fractional abundances of down to 0.01%.ConclusionsOur results show that detection of tumor specific TP53 mutations in low level ctDNA from HNSCC patients using ddPCR is technically feasible and provide ground for future research on ctDNA quantification for the use of diagnostic biomarkers in the posttreatment surveillance of HNSCC patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3424-0) contains supplementary material, which is available to authorized users.

A field guide for cancer diagnostics using cell‐free DNA: From principles to practice and clinical applications

“…Here, sampling error may play a role since mutated cfDNA molecules might not be present in each replicate . Therefore, samples should always be analyzed in triplicates if low allele frequencies are expected …”

Liquid biopsy in breast cancer: A comprehensive review

“…Analysis of ctDNA consists of quantitative and qualitative studies. Quantitative analysis of ctDNA using ddPCR assays is performed on the basis of the correlation between disease stage and ctDNA:cfDNA concentration ratio . On the other hand, qualitative studies use NGS to examine ctDNA for variations in cancer hotspots or the entire genome to examine early‐stage disease, response to treatment and prognosis .…”

Droplet digital polymerase chain reaction assay and peptide nucleic acid‐locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T‐cell lymphoma

“…Recently, the ddPCR assay has been widely used to detect genetic and epigenetic alterations . ddPCR can detect very rare sequences with high precision and sensitivity by partitioning individual target molecules within distinct compartments and, therefore, reduces the limitations of conventional methods such as classic real‐time quantitative PCR (qPCR) or the amplification refractory mutation system qPCR (ARMS qPCR) .…”

“…Although the sensitivity of NGS is superior to that of direct Recently, the ddPCR assay has been widely used to detect genetic and epigenetic alterations. [18][19][20][21] ddPCR can detect very rare sequences with high precision and sensitivity by partitioning individual target molecules within distinct compartments and, therefore, reduces the limitations of conventional methods such as classic real-time quantitative PCR (qPCR) or the amplification refractory mutation system qPCR (ARMS qPCR). [22][23][24] However, the PNA-LNA clamp method is a molecular probe-based PCR method; its unique design and allele-specific approach allow exceptionally high specificity and sensitivity.…”